Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
出版年份 2013 全文链接
标题
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
作者
关键词
-
出版物
BLOOD
Volume 121, Issue 24, Pages 4867-4874
出版商
American Society of Hematology
发表日期
2013-04-26
DOI
10.1182/blood-2013-03-490128
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
- (2013) P. Neelakantan et al. BLOOD
- Early landmark analysis of imatinib treatment in CML chronic phase: Less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome
- (2012) Lotta Ohm et al. AMERICAN JOURNAL OF HEMATOLOGY
- Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
- (2012) D. Marin et al. BLOOD
- How I treat newly diagnosed chronic phase CML
- (2012) J. Cortes et al. BLOOD
- Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
- (2012) N. Pemmaraju et al. HAEMATOLOGICA
- Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
- (2012) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
- (2012) B Hanfstein et al. LEUKEMIA
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
- (2012) R A Larson et al. LEUKEMIA
- Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients
- (2011) D. Milojkovic et al. BLOOD
- The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
- (2011) E. Jabbour et al. BLOOD
- Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
- (2011) Elias Jabbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
- (2011) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
- (2010) T. P. Hughes et al. BLOOD
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
- (2010) F J Giles et al. LEUKEMIA
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
- (2009) A. Quintas-Cardama et al. BLOOD
- Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
- (2009) Michele Baccarani et al. BLOOD
- Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
- (2009) L. Noens et al. BLOOD
- Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
- (2009) Yesid Alvarado et al. CANCER
- Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
- (2009) D. Milojkovic et al. HAEMATOLOGICA
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search